RT Journal Article
SR Electronic
A1 Shuman, Jill
T1 Infliximab Biosimilar Appears Safe and Effective Compared with Infliximab for RA
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 51
SP 11
OP 11
DO 10.1177/155989771451007
UL http://mdc.sagepub.com/content/14/51/11.1.abstract
AB Because Tumor necrosis factor inhibitors (TNFis) are expensive, however, there is currently much interest in lower-cost biosimilars—biological products that are highly similar to a licensed reference biological product with no clinically meaningful differences in safety, potency, and purity. This article presents results of a phase 3, randomized, double-blind, active comparator trial of the biosimilar BOW015 to its reference drug infliximab in patients with active rheumatoid arthritis.